678: GUT METAGENOME-DERIVED SIGNATURE PREDICTS HEPATIC DECOMPENSATION AND MORTALITY IN NASH-RELATED CIRRHOSIS

Suzanne R. Sharpton(University of California San Diego), Rohit Loomba(University of California San Diego), Tae Gyu Oh(University of Oklahoma Health Sciences Center), Egbert Madamba(University of California San Diego), Susy Kim(University of California San Diego), Ronald M. Evans(University of California San Diego), Michael Downes(Salk Institute for Biological Studies)
Gastroenterology
May 1, 2022
10.1016/s0016-5085(22)63407-3
Cited by 0

Related Papers

A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
|Hepatology|2017|1.9k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k